|
|
Stable solution of hyaluronate in a balanced salt medium
What is claimed is: 1. A physiological visco-elastic formulation consisting of sodium hyaluronate in an amount in the range of about 0.1% to about 5% by weight in a ...
|
|
|
Radiolabeled fusion toxins for cancer therapy
The present invention describes the synthesis and purification of a new class of compounds known as radiolabeled fusion toxins (RFT), in which both toxin and ...
|
|
|
Genetically modified cells expressing a TGF.beta. inhibitor, the cells being lung cancer cells
OF THE PREFERRED EMBODIMENT Lung cancers account for 30% of all death due to cancer in the United States (Ramanathan and Belani, 1997). The overall cure rate for lung ...
|
|
|
Auto-ligating oligonucleotide compounds
OF THE INVENTION The invention relates to a method and compositions for in situ formation of an effective antisense compound or probe on a target polynucleotide. C...
|
|
|
Nucleic acids encoding transcription factor APRF (acute phase response factor)
What is claimed: 1. An isolated DNA molecule which encodes a human APRF polypeptide having the amino acid sequence of SEQ ID No:1. 2. An isolated DNA molecule comprising ...
|
|
|
Antisense modulation of stat3 expression
OF THE INVENTION STAT3 plays an important role in cytokine signal transduction. Overexpression and/or constitutive activation of STAT3 is associated with a number of ...
|
|
|
Cold-active beta-galactosidase, the process for its preparation and the use thereof
The object of the present invention is to hydrolyse lactose by using a .beta.-galactosidase, which could overcome the above-mentioned drawbacks which are usually ...
|
|
|
Method of delivering powder transdermally with needless injector
What we claim is: 1. A method of therapeutic treatment, comprising transdermally delivering particles of a powdered therapeutic agent across skin tissue of a mammalian ...
|
|
|
Telomere repeat binding factors and diagnostic and therapeutic use thereof
The present invention provides vertebrate telomeric binding factors (TRFs) that bind to the TTAGGG repeat sequences of telomeres. Such TRFs comprise two key domains: a ...
|
|
|
Protease-activated receptor PAR4 (ZCHEMR2)
What is claimed is: 1. An isolated polynucleotide molecule that encodes a polypeptide comprising amino acid residues 48 to 78 of SEQ ID NO:2. 2. The isolated ...
|